RESELIGO

This brand name is authorized in Croatia, Estonia, Lithuania, Malta, Poland, Romania.

Active ingredients

The drug RESELIGO contains one active pharmaceutical ingredient (API):

1
UNII 6YUU2PV0U8 - GOSERELIN ACETATE
 

Goserelin is a synthetic analogue of naturally occurring LHRH. On chronic administration goserelin results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females.
 
Read more about Goserelin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
L02AE03 Goserelin L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AE Gonadotropin releasing hormone analogues
Discover more medicines within L02AE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EE Ravimiamet 1648403, 1648414, 1648425, 1648436
HR Agencija za lijekove i medicinske proizvode HR-H-731754823, HR-H-863040656
LT Valstybinė vaistų kontrolės tarnyba 1073399, 1078715
MT Medicines Authority AA565/93601, AA565/93602
PL Rejestru Produktów Leczniczych 100356580, 100356596
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W68571001, W68571002, W68572001, W68572002

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈